Abstract
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
Original language | English |
---|---|
Pages (from-to) | 797-799 |
Number of pages | 3 |
Journal | Journal of NeuroVirology |
Volume | 26 |
Issue number | 5 |
DOIs | |
State | Published - 1 Oct 2020 |
Keywords
- Coronavirus-19
- Guillain-Barré syndrome
- Neuromuscular disorders
- Polyneuropathy
- SARS-CoV-2